仁度生物 - Financials

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
+Revenue	177.0M	164.0M	304.0M	292.0M	250.0M
Revenue Growth %	7.9%	-46.1%	4.1%	16.8%	--
Total Revenue	177.0M	164.0M	304.0M	292.0M	250.0M
Cost Of Revenue	36.4M	30.8M	105.0M	74.2M	60.3M
+Gross Profit	140.6M	133.2M	199.0M	217.8M	189.7M
Gross Margin %	79.4%	81.2%	65.5%	74.6%	75.9%
Total Operating Cost	209.0M	184.0M	296.0M	228.0M	188.0M
Selling Expenses	89.9M	90.7M	123.0M	101.0M	80.9M
Admin Expenses	29.4M	26.8M	31.3M	25.8M	20.9M
Rd Expenses	39.2M	41.1M	34.2M	26.3M	23.7M
Finance Expenses	-6.2M	-8.1M	-4.4M	-1.5M	-90,600
+Operating Income	-14.6M	5.4M	27.5M	72.2M	69.1M
Operating Margin %	-8.2%	3.3%	9.0%	24.7%	27.7%
Non Operating Income	202,200	135,400	4,100	636,300	1.4M
Non Operating Expenses	838,800	815,100	829,700	382,700	321,300
Investment Income	11.2M	6.9M	8.3M	1.2M	1.1M
Fair Value Change Income	-237,300	661,600	978,600	--	--
Asset Disposal Income	136,300	-53,500	138,800	762,600	511,900
Asset Impairment Loss	2.7M	1.3M	2.5M	199,000	462,500
Other Income	6.4M	17.7M	10.0M	6.3M	5.5M
Income Before Tax	-15.2M	4.8M	26.7M	72.4M	70.2M
Income Tax	-7.4M	-3.5M	3.4M	7.8M	8.9M
+Net Income	-7.8M	8.3M	23.3M	64.6M	61.4M
Net Margin %	-4.4%	5.0%	7.7%	22.1%	24.6%
Net Income Attributable	-7.8M	8.3M	23.3M	64.6M	61.4M
Eps Basic	-0.20	0.21	0.62	2.15	2.05
Eps Diluted	-0.20	0.24	0.61	2.13	2.04

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash And Equivalents	262.0M	610.0M	299.0M	198.0M	172.0M
Trading Financial Assets	511.0M	50.2M	531.0M	--	--
Accounts Receivable	49.4M	76.8M	105.0M	55.3M	39.2M
Notes Receivable	--	259,900	--	--	--
Notes And Accounts Receivable	49.4M	77.1M	105.0M	55.3M	39.2M
Prepayments	5.9M	2.6M	4.2M	5.3M	778,300
Inventory	25.1M	28.6M	28.3M	19.4M	16.3M
Total Current Assets	885.0M	899.0M	973.0M	283.0M	230.0M
Fixed Assets	--	85.8M	91.2M	83.4M	52.7M
Fixed Assets Total	77.7M	85.8M	91.2M	83.4M	52.7M
Construction In Progress	--	--	--	--	18.4M
Construction In Progress Total	409,500	--	--	--	18.4M
Intangible Assets	409,600	449,900	662,200	597,000	519,600
Long Term Deferred Expenses	6.7M	8.3M	3.7M	3.9M	698,000
Total Non Current Assets	110.0M	156.0M	116.0M	96.1M	80.4M
Total Assets	994.0M	1.1B	1.1B	379.0M	311.0M
Short Term Borrowings	--	--	--	--	3.8M
Accounts Payable	3.0M	4.1M	11.4M	9.8M	8.0M
Advance Receipts	--	--	--	--	--
Contract Liabilities	9.0M	5.6M	7.3M	9.2M	14.4M
Total Current Liabilities	74.4M	78.4M	95.5M	66.3M	77.1M
Total Non Current Liabilities	8.1M	13.5M	31.9M	24.6M	18.7M
Total Liabilities	82.5M	92.0M	127.0M	90.9M	95.8M
Paid In Capital	40.0M	40.0M	40.0M	30.0M	30.0M
Capital Reserve	777.0M	774.0M	776.0M	135.0M	127.0M
Surplus Reserve	14.0M	12.9M	11.4M	11.4M	6.0M
Retained Earnings	116.0M	136.0M	135.0M	111.0M	52.2M
Equity Attributable	912.0M	963.0M	961.0M	288.0M	215.0M
Total Equity	912.0M	963.0M	961.0M	288.0M	215.0M

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash From Sales	201.0M	199.0M	260.0M	287.0M	264.0M
Tax Refunds Received	--	2,900	427,700	--	--
Total Operating Cash Inflow	211.0M	213.0M	276.0M	297.0M	277.0M
Cash Paid For Goods	21.5M	18.5M	90.3M	71.6M	63.5M
Cash Paid To Employees	83.3M	91.2M	100.0M	80.9M	51.4M
Taxes Paid	6.9M	7.3M	19.3M	17.9M	9.2M
Total Operating Cash Outflow	187.0M	195.0M	280.0M	243.0M	184.0M
Operating Cash Flow	24.4M	17.2M	-4.1M	54.4M	92.6M
Total Investing Cash Inflow	1.4B	1.1B	316.0M	44.2M	115.0M
Total Investing Cash Outflow	1.7B	787.0M	858.0M	67.6M	95.9M
Investing Cash Flow	-322.0M	302.0M	-542.0M	-23.5M	19.1M
Cash From Borrowings	--	--	--	--	3.8M
Dividends And Interest Paid	11.7M	5.0M	--	53,200	138,100
Debt Repayments	--	--	--	3.8M	--
Total Financing Cash Inflow	--	--	676.0M	3.0M	21.8M
Total Financing Cash Outflow	50.6M	9.0M	28.4M	8.0M	2.8M
Financing Cash Flow	-50.6M	-9.0M	647.0M	-5.0M	19.0M
Net Change In Cash	-348.0M	311.0M	101.0M	25.7M	130.0M
Ending Cash Balance	262.0M	609.0M	299.0M	197.0M	172.0M
Capex	10.5M	20.4M	21.2M	26.5M	15.5M